MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/12/26
MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast InjuriesGlobeNewsWire • 12/10/25
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/20/25
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®GlobeNewsWire • 11/03/25
MediWound Announces $30 Million Registered Direct Offering of Ordinary SharesGlobeNewsWire • 09/29/25
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in AustraliaGlobeNewsWire • 09/25/25
MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association CongressGlobeNewsWire • 09/02/25
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 08/20/25
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/25
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg UlcersGlobeNewsWire • 08/13/25
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/21/25
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg UlcersGlobeNewsWire • 05/13/25